Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC

Video

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Daniel J. George, MD, professor of Medicine, professor in Surgery, Duke Cancer Institute, discusses the use of niraparib (Zejula) for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA and ATM mutations.

The phase 2 Galahad trial (NCT02854436) evaluated niraparib in patients with a documented biallelic DNA-repair anomaly, including those with BRCA and ATM mutations, among other defects, George explains.

Niraparib demonstrated a high clinical response rate in this patient population, George continues. Additionally, both the objective response rate and duration of response were beneficial, George concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,